Table 1.
List of compounds used as LAI treatment and their on– / off–label indications based on diagnoses in the study cohort
| Pharmaceutical Compound | Dosage | Schizophrenia | Bipolar Disorder | Major depression | Obsessive compulsive Disorder | Personality Disorder | Neurodevelopmental Disorder | Neurocognitive Disorder | Other |
|---|---|---|---|---|---|---|---|---|---|
| Haloperidol Decanoatea (FGA) | 12,5–300 mg/monthly | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
| Zuclopenthixol Decanoateb (FGA) | 100–600 mg/biweekly | ON LABEL | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
| Fluphenazine Decanoatec (FGA) | 12,5–100 mg/biweekly | ON LABEL | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
| Risperidone LAId (SGA) | 25–50 mg/biweekly | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
| Paliperidone Palmitated (SGA) | 25–150 mg/monthly | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
| Olanzapine Pamoated (SGA) | 300–405 mg/monthly | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
| Aripiprazole LAId (SGA) | 400 mg/monthly | ON LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL | OFF LABEL |
aHaloperidol Decanoate is licensed for the maintenance treatment of Schizophrenia and Schizoaffective Disorder
bZuclopenthixol Decanoate is licensed for acute and chronic Schizophrenia and other dissociative syndromes characterized by symptoms such as hallucination, agitation, psychomotor excitement, hostility, aggressiveness and affective disturbances. Manic phase of manic–depressive psychosis
cFluphenazine decanoate is licensed for the treatment of Schizophrenia and manic syndromes
dAll SGA LAIs are licensed for the maintenance treatment of adults diagnosed with Schizophrenia
All licensing information refers to the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), FGA First–Generation Antipsychotic, SGA Second–Generation Antipsychotic